Skip to main content
BDMD
NASDAQ Industrial Applications And Services

Baird Medical Dismisses Auditor, Discloses Material Weaknesses in Financial Controls

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$0.947
Mkt Cap
$37.093M
52W Low
$0.9
52W High
$7.262
Market data snapshot near publication time

summarizeSummary

Baird Medical Investment Holdings Ltd. dismissed its auditor and appointed a new one, simultaneously disclosing material weaknesses in its internal financial controls.


check_boxKey Events

  • Auditor Dismissed

    The company dismissed its former independent registered public accounting firm, Kreit & Chiu CPA LLP, effective February 10, 2026.

  • New Auditor Appointed

    Guangdong Prouden CPAs GP was appointed to serve as the new independent registered public accounting firm for the year ended December 31, 2025.

  • Material Weaknesses Disclosed

    The company disclosed material weaknesses in its internal control over financial reporting, including insufficient financial reporting personnel with U.S. GAAP and SEC knowledge, and a lack of comprehensive accounting policies and procedures.


auto_awesomeAnalysis

Baird Medical Investment Holdings Ltd. has dismissed its independent registered public accounting firm, Kreit & Chiu CPA LLP, and appointed Guangdong Prouden CPAs GP. While there were no disagreements with the former auditor, the company disclosed material weaknesses in its internal control over financial reporting. These weaknesses include a lack of sufficient financial reporting personnel with U.S. GAAP and SEC reporting knowledge, and inadequate accounting policies and procedures. This change, coupled with the disclosed control deficiencies, raises concerns about the reliability of the company's financial reporting and its ability to meet regulatory standards, which could impact investor confidence.

At the time of this filing, BDMD was trading at $0.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $37.1M. The 52-week trading range was $0.90 to $7.26. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BDMD - Latest Insights

BDMD
Apr 24, 2026, 4:35 PM EDT
Filing Type: 20-F
Importance Score:
9
BDMD
Feb 10, 2026, 7:59 AM EST
Filing Type: 6-K
Importance Score:
8
BDMD
Jan 16, 2026, 4:32 PM EST
Filing Type: 424B3
Importance Score:
9